Last reviewed 2026-05-14 · How we verify

L50/H12.5/A5

L50/H12.5/A5 is a fixed-dose combination of three antihypertensive agents that work synergistically to reduce blood pressure through multiple pathways.

L50/H12.5/A5 is a fixed-dose combination of three antihypertensive agents that work synergistically to reduce blood pressure through multiple pathways. Used for Hypertension in patients requiring triple antihypertensive therapy.

At a glance

Mechanism of action

This combination likely contains a long-acting calcium channel blocker, an angiotensin II receptor blocker, and a thiazide or thiazide-like diuretic. Each component targets different mechanisms of hypertension: vasodilation, renin-angiotensin system inhibition, and sodium/fluid reduction, respectively. The fixed-dose formulation is designed to improve medication adherence and efficacy in patients requiring triple therapy.

Approved indications

• Hypertension in patients requiring triple antihypertensive therapy

Common side effects

• Dizziness
• Peripheral edema
• Headache
• Fatigue
• Hyperuricemia

Key clinical trials

• MK-0954E Study in Participants With Hypertension (MK-0954E-357) (PHASE3)
• MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• L50/H12.5/A5 CI brief — competitive landscape report
• L50/H12.5/A5 updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI